About | HeinOnline Law Journal Library | HeinOnline Law Journal Library | HeinOnline

B-283939 1 (2000-01-27)

handle is hein.gao/gaocrptakyw0001 and id is 1 raw text is: 



                   -e GeAtOa
 __Comptroller General
                                                                of the United States
United States General Accounting Office
Washington, DC 20548



         Decision


         Matter of: SmithKline Beecham Corporation

         File:      B-283939

         Date:      January 27, 2000


         John E. Daniel, Esq., Morgan, Lewis & Bockius, for the protester.
         Thomas L. McGovern III, Esq., and Joy E. Sturm, Esq., Hogan & Hartson, for Glaxo
         Wellcome Inc.; and David C. Hammond, Esq., Powell, Goldstein, Frazer & Murphy,
         for Hoechst Marion Roussel, the intervenors.
         Barbara J. Stuetzer, Esq., and Phillipa L. Anderson, Esq., Department of Veterans
         Affairs, for the agency.
         Ralph 0. White, Esq., and Christine S. Melody, Esq., Office of the General Counsel,
         GAO, participated in the preparation of the decision.
         DIGEST

         Protester's challenge to the price evaluation scheme included in a solicitation for
         prescription drugs that anticipates evaluation of a per-dose price based on the only
         use for which all three of the competing drugs are approved by the Food and Drug
         Administration is denied, even though the evaluation does not consider certain uses
         of the solicited drugs that will have a different cost profile, where the per-dose price
         requested provides a common basis for evaluating prices, the agency has no basis for
         providing estimates for the other uses of these drugs, and the protester has not
         established that the solicitation's approach will produce a materially misleading
         result.
         DECISION

         SmithKline Beecham Corporation (SKB) protests the terms of request for proposals
         (RFP) No. RFP-797-NC-99-0020, issued by the Department of Veterans Affairs (VA)
         for 5-Hydroxtryptamine (5HT3) receptor antagonists, used for the treatment of
         nausea and vomiting (emesis) resulting from chemotherapy. SKB argues that the
         RFP's price evaluation methodology will not identify the proposal that will provide
         the actual lowest price to the government.


We deny the protest.

What Is HeinOnline?

HeinOnline is a subscription-based resource containing thousands of academic and legal journals from inception; complete coverage of government documents such as U.S. Statutes at Large, U.S. Code, Federal Register, Code of Federal Regulations, U.S. Reports, and much more. Documents are image-based, fully searchable PDFs with the authority of print combined with the accessibility of a user-friendly and powerful database. For more information, request a quote or trial for your organization below.



Contact us for annual subscription options:

Already a HeinOnline Subscriber?

profiles profiles most